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INTRODUCTION 
Summary 
Objective The G protein-coupled receptor 39 (GPR39) has recently been identified as the receptor 
for obestatin, a peptidic hormone involved in energy homeostasis. However, the expression levels of 
this receptor in human adipose tissue in obesity and obesity-associated type 2 diabetes mellitus 
(T2DM) remain unknown. Therefore, we evaluated the actual presence of GPR39 mRNA in human 
adipose tissue and whether GPR39 expression levels are altered in obesity and obesity-associated 
T2DM. 
Design Omental adipose tissue biopsies obtained from 15 women were used in the study. 
Patients were classified as lean (body mass index 20·8 ± 1·0 kg/m2), obese normoglycaemic 
(body mass index 48·4 ± 2·1 kg/m2) and obese T2DM patients (body mass index 52·6 ± 4·9 
kg/m2). Anthropometric measurements and biochemical profiles were assessed for each subject. 
Real-time RT-PCR analyses were performed to quantify transcript levels of GPR39 and 
adiponectin.  
Results Obese T2DM patients exhibited significantly lower GPR39 expression levels compared 
to lean (P= 0·016) and obese normoglycaemic subjects (P= 0·008), while no differences between 
lean and obese normoglycaemic patients were observed. The mRNA expression levels of GPR39 
were negatively correlated to fasting glucose concentrations (r=−0·581, P=0·023), while 
exhibiting a positive correlation to adiponectin mRNA expression levels (r=0·674, P = 0·006). 
Conclusion GPR39 is expressed in human adipose tissue. The reduced expression levels of GPR39 
in omental adipose tissue observed in obese patients with T2DM suggest an involvement of 
obestatin signalling in glucose homeostasis and T2DM development. 
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 The G protein-coupled receptor 39 (GPR39) was isolated from human genomic libraries closely 
related to the growth hormone secretagogue receptor (GHSR), i.e. the receptor for ghrelin and 
neurotensin receptor-1.1 A highly conserved single-copy gene mapped to human chromosome 2 
encodes this receptor and its expression in multiple tissues, including brain and other peripheral 
organs (such as stomach or intestine), is consistent with a role in energy balance regulation.2
The endogenous ligand of GPR39 was unknown until recently, when Zhang et al.3 identified 
obestatin, an appetite- and gastrointestinal motility-suppressing peptide derived from proghrelin. In 
contrast to ghrelin, which stimulates food intake and obesity in rats,4 obestatin appears to act as an 
anorexic hormone by decreasing food intake, gastric emptying and body weight gain.3 These 
findings support a role for the involvement of obestatin and ghrelin in energy homeostasis. 
However, the exact contribution of GPR39 needs to be further disentangled.5
Obesity is often associated with insulin resistance with type 2 diabetes mellitus (T2DM) being one of 
the most frequent obesity-associated conditions. It has been proposed that ghrelin and obestatin play a 
role in the modulation of the release of insulin and glucagon;4,6–8 therefore, representing potential 
targets for obesity treatment.3
To date, the expression of GPR39 in adipose tissue has not been described. Since body fat 
represents a key peripheral organ in energy balance, the aim of our study was (i) to decipher 
whether GPR39 is actually expressed in adipose tissue, and (ii) to identify the influence of obesity 
and obesity-associated T2DM on the expression levels of GPR39. 
 
SUBJECTS AND METHODS  
 
Experimental subjects 
Fifteen adipose tissue samples obtained from the omental depot of lean and obese women were used 
in the study. Patients were classified as obese according to both body mass index (BMI >! 30 kg/m2 ) 
and body fat percentage (BF >! 35%). BMI was calculated as weight in kilograms divided by the 
square of height in metres and body fat was estimated by air-displacement-plethysmography (Bod-
Pod®, Life Measurements, Concord, CA, USA). To determine the effects of T2DM on gene 
expression, obese volunteers were further subclassified into two groups according to the presence or 
not of T2DM (Table 1). All lean and obese normoglycaemic (NG) patients had plasma glucose 
concentrations below 5·6 mmol/l after fasting and below 7·8 mmol/l 2 h after an oral glucose 
tolerance test (OGTT). T2DM was established on the basis of fasting glucose concentrations >- 7·0 
mmol/l and glycaemia >- 11·2 mmol/l 2 h after an OGTT. T2DM subjects were not on insulin 
therapy or on medications likely to influence endogenous insulin levels. The samples were collected 
from patients undergoing either bariatric surgery or Nissen fundoplication at the Clínica 
Universitaria de Navarra. Both interventions were carried out via a laparoscopic approach. Tissue 
samples were immediately frozen in liquid nitrogen and stored at −80 °C for gene expression 
analysis. The study was approved, from an ethical and scientific standpoint, by the hospital’s ethical 
committee responsible for research and the informed consent of participants was obtained. 
Blood assays 
Blood was obtained by venipuncture after an overnight fast. Serum glucose was analysed by an 
automated analyser (Hitachi Modular P800, Roche, Basel, Switzerland), with quantification being 
based on enzymatic colorimetric reactions. Serum insulin was measured by means of an enzyme-
amplified chemiluminescence assay (IMMULITE®, Diagnostic Products Corp., Los Angeles, CA, 
USA). Total cholesterol and triglyceride concentrations were determined by enzymatic 
spectrophotometric methods (Boehringer Mannheim, Mannheim, Germany). High-density 
lipoprotein cholesterol (HDL-C) was quantified by a colorimetric method in a Beckman Synchron® 
CX analyser (Beckman Instruments, Ltd, Bucks, UK). Low-density lipoprotein (LDL) cholesterol 
was calculated by the Friedewald formula. Adiponectin was determined using a commercially 
available ELISA kit (Biovendor, Heilderberg, Germany). Intra- and interassay coefficients of 
variation were 6·7% and 7·8%, respectively. Leptin was measured by a double-antibody RIA 
method (Linco Research Inc., St. Charles, MO, USA). Intra- and interassay coefficients of 
variation were 5·0% and 4·5%, respectively. 
 
RNA extraction and real-time PCR 
Adipose tissue RNA isolation was performed by homogenization with an ULTRA-TURRAX® T 
25 basic (IKA® Werke GmbH, Staufen, Germany) using TRIzol® Reagent (Invitrogen, Barcelona, 
Spain). Samples were purified using the RNeasy Mini kit (Qiagen, Barcelona, Spain) and treated 
with DNase (RNase-free DNase Set, Qiagen). For first strand cDNA synthesis, constant amounts of 
1 µg of total RNA were reverse transcribed in a 20-µl final volume using random hexamers (Roche) 
as primers and 200 units of M-MLV reverse transcriptase (Invitrogen) as previously described.9
The transcript levels for GPR39 and adiponectin were quantified by real-time RT-PCR (7300 Real 
Time PCR System, Applied Biosystems, Foster City, CA, USA). Primers and probes were designed 
using the software Primer Express 1·0 (Applied Biosystems) (Table 2). Probes were designed to 
hybridize between exons to ensure the detection of the corresponding transcript avoiding genomic 
DNA amplification. The cDNA was amplified at the following conditions: 95 °C for 10 min, followed 
by 45 cycles of 15 s at 95 °C and 1 min at 59 °C, using the TaqMan® Universal PCR Master Mix 
(Applied Biosystems). The primer and probe concentrations for gene amplification were 300 nmol/l 
and 200 nmol/l, respectively. All results were normalized to the levels of 18S rRNA (Applied 
Biosystems) and relative quantification was calculated using the ∆∆Ct formula. Relative mRNA 
expression was expressed as fold expression over the calibrator sample (average of gene expression 
corresponding to the lean group). All samples were run in triplicate and the average values were 
calculated. 
 
Data analysis 
Data are presented as mean ± standard error of the mean (SEM). Differences between groups 
were analysed by Kruskal–Wallis tests followed by Mann–Whitney’s U-tests. Pearson’s correlation 
coefficients (r) were computed to explore the correlation between two variables. The calculations were 
performed using the SPSS/Windows version 11·0.1 statistical package (SPSS Inc., Chicago, IL, USA). 
A P-value of < 0·05 was considered statistically significant. 
 RESULTS 
The obese NG patients included in our study showed significantly higher body fat (BF), insulin 
and leptin concentrations, while exhibiting lower HDL-C levels as compared to the lean subjects 
(Table 1). Obese T2DM patients had significantly (P < 0·05) increased glucose concentrations in 
the fasting state and 2 h after an OGTT, and significantly reduced (P < 0·05) adiponectin levels in 
comparison to the lean and obese NG volunteers (Table 1). The hypoadiponectinaemia observed in 
the obese T2DM patients is consistent with the proven beneficial insulin-sensitizing effects of this 
adipokine.10
Real-time PCR analysis indicated that GPR39 is expressed in all samples of adipose tissue, 
providing evidence, for the first time, of the presence of GPR39 in adipose tissue. Expression 
levels were significantly lower in obese T2DM patients compared to lean (P = 0·016) and obese 
NG subjects (P = 0·008). Interestingly, a trend towards a twofold increase in GPR39 expression 
was observed in omental adipose tissue of obese NG patients compared to lean individuals (Fig. 
1). In addition, expression levels of GPR39 were negatively correlated to fasting glucose 
concentrations (r=–0·581, P= 0·023) and positively correlated to adiponectin mRNA levels in 
adipose tissue (r = 0·674, P = 0·006). No statistically significant correlation between adipose 
tissue GPR39 expression and body weight, BMI or BF was observed. Taken together, these data 
suggest the participation of GPR39 signalling in glucose homeostasis and T2DM development. 
 
DISCUSSION 
Obestatin, a recently identified peptide derived from the same gene as ghrelin, has been related to 
energy balance control.3 After differential proteolytic modification, the two hormones exert 
opposing actions on weight regulation through the activation of distinct receptors. For this reason, 
we analysed the gene expression level of GPR39, the receptor for obestatin, in human adipose 
tissue samples. In addition, we further gained insight into the influence of obesity and T2DM on 
the expression of this receptor. 
A significant correlation between insulin and obestatin concentrations in the postnatal pancreas has 
been described previously, raising the possibility that obestatin may play a role in the control of 
insulin secretioná Several analyses have been carried out exploring the relation between ghrelin and 
glucose homeostasis, but results are contradictory. It has been reported that ablation of ghrelin 
contributes to an enhanced glucose-induced insulin secretion,7 which is in agreement with data 
describing that ghrelin administration inhibited glucoseinduced insulin secretion.11 In contrast, 
another study has shown a dual effect of ghrelin with low concentrations inhibiting insulin secretion 
of mouse pancreatic islets, while high ghrelin levels resulting in insulin stimulation.12 In the light of 
the ghrelin-obestatin antagonism these differences might be attributed to the intricate balance of 
obestatin and ghrelin in the regulation of energy homeostasis and the difficulties to extract clear-cut 
conclusions when the preproghrelin gene is removed. 5,6
GPR39 has shown a high degree of constitutive signalling through the serum response element 
(SRE) pathway. 13 A close interaction between phosphatidylinositol 3-kinase (PI3K) and SRE-
mediated transcription has been previously described14 with the PI3K pathway being responsible for 
a fraction of SRE activation through GPR39. Furthermore, the PI3K pathway is known to play a 
critical role in the effects of insulin on glucose metabolism.14 Several defects in the insulin 
signalling pathway such as reduction of PI3K15 and Akt kinase16 activities have been reported in 
T2DM patients. Therefore, a reduced expression of GPR39 and, hence, a decreased PI3K activity 
may contribute to the defective insulin signalling that takes place in adipose tissue of T2DM 
patients. 
In summary, our findings show for the first time that GPR39 mRNA is expressed in adipose tissue 
and that it is reduced in obese T2DM patients. Moreover, the lack of correlation of GPR39 
expression with body weight, BMI and BF together with the significant negative correlation to 
glycaemia points more towards the involvement of obestatin signalling in glucose homeostasis and 
T2DM development rather than in body weight control. Determining the effects of circulating 
obestatin and understanding the signalling pathway activated via its receptor GPR39 will shed 
more light on the complex neuroendocrine control of energy homeostasis and body weight. 
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Table 1. Anthropometric and biochemical parameters of lean and obese subjects 
 Lean (n = 5) Normoglycaemic 
obese (n = 5) 
T2DM obese (n = 5)
Age (years) 38 ± 4 36 ± 5 43 ± 3 
BMI (kg/m2) 20·8 ± 1·0 48·4 ± 2·1* 52·6 ± 4·9* 
Body fat (%) 28·7 ± 3·0 56·3 ± 1·1* 54·0 ± 1·8* 
Fasting glucose (mg/dl) x 0·056 
= mmol/l 5·1 ± 0·2 4·9 ± 0·3 7·6 ± 0·6 *† 
2 h OGTT glucose (mg/dl) x 
0·056 = mmol/l 6·0 ± 0·6 6·4 ± 0·3 14·7 ± 2·4*† 
Fasting insulin (µU/ml) x 7·18 
= mmol/l 53·1 ± 11·5 129·2 ± 33·7* 162·3 ± 45·9* 
2 h OGTT insulin (µU/ml) x 
7·18 = mmol/l 75·4 ± 12 740·3 ± 307·3* 651 ± 133·5* 
Triglycerides (mg/dl) x 0·0113 = 
mmol/l 0·86 ± 0·1 1·2 ± 0·1 1·5 ± 0·2 
Total cholesterol (mg/dl) x 0·026 
= mmol/l 4·8 ± 0·3 4·8 ± 0·4 5·2 ± 0·3 
HDL cholesterol (mg/dl) x 
0·02586 = mmol/l 1·4 ± 0·1 0·98 ± 0·1* 0·99 ± 0·1* 
LDL cholesterol (mg/dl) 3·7 ± 0·2 3·8 ± 0·3 4·1 ± 0·2 
Leptin (ng/ml) 9·1 ± 1·7 57·6 ± 7·6* 69·4 ± 19·6* 
Adiponectin (µg/ml) 11·2 ± 2·4 8·8 ± 0·8 4·8 ± 0·5*† 
 
Data are mean ± standard error of the mean. Differences between both groups were by Kruskal–Wallis 
followed by Mann–Whitney’s U-tests. *P < 0·05 vs. lean. †P < 0·05 vs. normoglycaemic obese. 
BMI, body mass index; HDL, high-density lipoprotein; LDL, low-density lipoprotein; OGTT, oral 
glucose tolerance test; T2DM, type 2 diabetes mellitus. 
 
 
 
 
 
 
 Table 2. Sequences of the primers and TaqMan probes 
Gene (GenBank accession) Oligonucleotide sequence (5′−3′) 
GPR39 (NM_001508)  
Forward TTCCTGAGGCTGATTGTTGTGA 
Reverse GCCATGATCCTCCGAATCTG 
Probe FAM-ATTGGCCGTATGCTGGATGCCCA-TAMRA 
ADIPOQ (NM_004797)  
Forward GGAGATCCAGGTCTTATTGGTCCTA 
Reverse CCTTGGATTCCCGGAAAGC 
Probe FAM-ACATCGGTGAAACCGGAGTACCCGG-TAMRA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
Fig. 1 Real-time RT-PCR analysis of GPR39 transcript levels in omental adipose tissue of lean (LN), 
normoglycaemic obese (NG OB) and diabetic obese (T2DM OB) volunteers (n = 5 per group). Bars 
represent the mean ± SEM of the ratio between GPR39–18S rRNA. The expression of GPR39 in lean 
subjects was assumed to be 1. Differences between groups were analysed by Kruskal–Wallis 
followed by Mann–Whitney U-tests. *P < 0·05 vs. LN. §P < 0·05 vs. NG OB. 
